tDCS + CCFES for Stroke-related Hand Weakness
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to help people who struggle to open their hands after a stroke. It tests three different combinations of brain stimulation (Transcranial Direct Current Stimulation, or tDCS) and therapy to determine which one best improves hand movement. Participants may qualify if they had a stroke within the last 6 to 24 months, can move their shoulder and elbow, and can slightly open their fingers and wrist.
As an unphased trial, participants contribute to innovative research that could lead to new treatment options.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are on medications that lower the seizure threshold, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that transcranial direct current stimulation (tDCS) is generally safe and well-tolerated. Studies have found that tDCS can safely improve hand movement in stroke patients. This method uses a small electrical current to stimulate the brain and is non-invasive, meaning it doesn't require surgery or entering the body. Most people experience only mild side effects, like a tingling sensation on the scalp where the device is placed.
Research also supports the safety of using tDCS in less traditional ways. It has been used safely at home, proving practical for everyday use. Most users find it comfortable, with few negative effects.
Both conventional and unconventional tDCS are used together with CCFES, a therapy that uses electrical stimulation to help muscles move. Past research suggests this combination is safe, with only minor side effects usually reported.
Overall, previous studies consider these treatments safe, with participants generally having a positive experience and few issues.12345Why are researchers excited about this trial?
Researchers are excited about these treatments because they offer a fresh approach to tackling stroke-related hand weakness. Most current treatments involve physical therapy and sometimes medication to help regain hand function. Unlike these standards, the trial explores transcranial direct current stimulation (tDCS) combined with contralaterally controlled functional electrical stimulation (CCFES). The active conventional tDCS approach targets the injured side of the brain, while the unconventional method targets the uninjured side. This electrical stimulation aims to enhance brain plasticity and hand function more effectively than traditional methods. This innovative combination could offer a more targeted and potentially quicker recovery path for stroke patients.
What evidence suggests that this trial's treatments could be effective for stroke-related hand weakness?
This trial will compare different approaches to using transcranial direct current stimulation (tDCS) combined with Functional Electrical Stimulation (FES) to improve hand function after a stroke. Research has shown that tDCS with therapy can enhance hand movement. Participants may receive either the conventional tDCS montage, which stimulates the brain's affected side, or the unconventional montage, which targets the unaffected side. Studies have found that applying tDCS to the affected side can significantly enhance hand movement, with some patients experiencing a 10-point increase in function scores. Other studies suggest that using tDCS on the unaffected side can also slightly boost motor skills and grip strength. Evidence indicates that combining tDCS with FES leads to better recovery than using either method alone. Overall, both traditional and alternative tDCS methods show promise in helping stroke patients regain hand function.26789
Who Is on the Research Team?
David A Cunningham, PhD
Principal Investigator
MetroHealth Medical Center and Case Western Reserve University
Are You a Good Fit for This Trial?
This trial is for adults aged 21-90 who've had a stroke within the last 6-24 months, resulting in upper limb weakness but can still open their hand somewhat. They must be able to follow commands, remember things short-term, and sit unassisted. Excluded are those with seizure disorders, other neurological conditions, implanted electronic devices, pregnancy, recent Botox injections in the arm muscles or severe cognitive impairments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of three tDCS protocols combined with CCFES-mediated occupational therapy for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Active conventional tDCS montage plus CCFES
- Active unconventional tDCS montage plus CCFES
- CCFES with Occupational Therapy
- Sham tDCS plus CCFES
Active conventional tDCS montage plus CCFES is already approved in United States, European Union for the following indications:
- Post-stroke upper extremity hemiplegia
- Motor function rehabilitation
- Post-stroke motor function rehabilitation
- Neurological rehabilitation
Find a Clinic Near You
Who Is Running the Clinical Trial?
MetroHealth Medical Center
Lead Sponsor